Shamik Ghosh

Shamik Ghosh is the current VP of Preclinical Development at Rejuvenation Technologies. Shamik has over 10 years of experience in the biotech industry, with a focus on immunology and small molecule therapeutics.

Shamik started their career at Vyome Therapeutics Inc., where they served as Senior Director/Director. In this role, Shamik was responsible for raising series B and C funding for small molecule platform development, as well as overseeing a team of 8 direct reports. Shamik also played a key role in evaluating global commercial service providers and coordinating with GXP auditors for CRO audits, SOP compliance, and CAPA review.

In addition to their managerial responsibilities, Shamik also led the early discovery effort of a dual active molecule for the treatment of inflammatory acne. This included In Silico screening, SAR, In vitro assays, Secretome analysis, In vivo validation, and PK/PD studies. Shamik also developed and executed non-clinical safety/toxicology plans in small and large animal models in support of all stages of drug development following ICH/FDA guidance.

Shamik has also authored multiple scientific and clinical manuscripts, and has presented at multiple international conferences. In 2018, Shamik completed an out-licensing deal with a large pharma company for an antimicrobial asset.

Ghosh Shamik did their post-doctoral fellowship in microbiology and immunology from Harvard Medical School. Shamik has also completed their MBA in entrepreneurship from Babson F.W. Olin Graduate School of Business. Presently, they are pursuing their Ph.D. in immunology from Jawaharlal Nehru Vishvavidyalaya.

Some of their coworkers include Apoorva Shankar - Life Science Research Associate, Tanya Velasco - Life Science Research Associate II, and Bo Yang - Research Fellow. Their manager is John Ramunas, Founder & CEO.